Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2R0UM
|
|||
| Drug Name |
Naratuximab emtansine
|
|||
| Synonyms |
DEBIO 1562
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 2 | [1] | ||
| Company |
Debiopharm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte antigen CD37 (CD37) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02564744) Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Debiopharm. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.